rs4519796 — SLC2A9 SLC2A9 rs4519796

SLC2A9 rs4519796 — A Second Intronic Tag for the GLUT9 Urate-Reabsorption Haplotype

Your kidneys filter roughly 700 mg of uric acid every day and then reabsorb most of it — resetting your blood urate baseline with each filtration cycle. The protein that handles the largest share of that reabsorption is GLUT9¹¹ GLUT9
Glucose Transporter 9, encoded by SLC2A9. Despite its name, GLUT9's dominant physiological role in the adult kidney is voltage-driven urate transport, not glucose, encoded by the SLC2A9 gene on chromosome 4. rs4519796 sits 292 base pairs upstream of a well-characterised intronic SLC2A9 risk variant (rs6814664), in the same intronic region of the gene, and carries an identical population-frequency signature: the A allele is most common in East Asians (~92%), who have the world's highest rates of gout, and least common in Africans (~34%), who historically have had lower gout burden. This gradient is the hallmark of SLC2A9 urate-reabsorption risk haplotypes.

The Mechanism

SLC2A9 encodes two kidney isoforms — GLUT9a on the basolateral membrane of proximal tubule cells, which returns reabsorbed urate to the circulation, and GLUT9b on the apical membrane, which accepts urate from the tubular lumen. Together they form the dominant urate-recapture system: filtered urate enters the lumen, URAT1 shuttles it into the tubular cell, and GLUT9a pumps it back into blood. Variants in the intronic and regulatory regions of SLC2A9 modulate how much GLUT9 is expressed, rather than changing the protein's sequence. Fine-mapping of the SLC2A9 locus²² Fine-mapping of the SLC2A9 locus
Wei et al. Abundant local interactions in the 4p16.1 region. Hum Mol Genet, 2014 has identified multiple independent signals with epistatic interactions, collectively explaining more urate variance than any single SNP. rs4519796 is positioned within this same regulatory window and is a likely tag for haplotypes that increase GLUT9 expression or transport activity, resulting in more urate being retained per filtration cycle.

Because no published study has directly tested rs4519796 in isolation, the evidence for this specific variant rests on its position within the SLC2A9 risk locus and its population frequency gradient — not on a direct genotype-phenotype association study. This places rs4519796 in the emerging evidence tier: the locus effect is established, but this variant's independent contribution has not been formally quantified.

The Evidence

The SLC2A9 locus is the most replicated genetic determinant of serum urate in humans. Vitart et al. (2008)³³ Vitart et al. (2008)
Vitart V et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nature Genetics, 2008 showed that intronic SLC2A9 variants explain 1.7–5.3% of serum urate variance across Croatian, UK, and German samples and associate with reduced fractional excretion of uric acid — confirming that the mechanism is impaired renal clearance, not overproduction.

Döring et al. (2008)⁴⁴ Döring et al. (2008)
Döring A et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nature Genetics, 2008 found that SLC2A9 intronic variants in introns 4 and 6 explain approximately 1.2% of serum urate variance in men and a striking 6% in women. Effect sizes were −0.23 to −0.36 mg/dL per protective allele, with women showing up to twice the effect size of men. SLC2A9 isoform 2 expression explained 3.5% of urate variance in men and 15% in women — likely reflecting estrogen-mediated regulation of GLUT9 in proximal tubule cells.

Across the SLC2A9 locus as a whole, Yang et al. (2010)⁵⁵ Yang et al. (2010)
Yang Q et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet, 2010 confirmed that SLC2A9 and ABCG2 are the only two loci reaching genome-wide significance for gout across 28,283 participants in a multi-cohort meta-analysis, underscoring the transporter axis as the dominant genetic driver of gout susceptibility.

Sex-specific note: The sex-divergent effect of SLC2A9 intronic variants is one of the best-replicated gene-by-sex interactions in metabolic genetics. Women carrying the risk haplotype — who have lower baseline urate than men and therefore face a proportionally larger relative increase — should treat this variant's significance as equivalent to, or greater than, the warning level applied to men with the same genotype.

Practical Actions

The actionable levers for A-allele carriers mirror those for adjacent SLC2A9 variants: reduce the urate substrate that the overactive GLUT9 transporter is positioned to recapture. Organ meats (liver, kidney, sweetbreads) and red meat are the highest-purine dietary sources. Alcohol — especially beer, which combines brewer's yeast purines with ethanol's direct urate-retention effect — is the most potent modifiable trigger. High-fructose intake drives urate synthesis through inosine monophosphate generation and competes with urate for SLC2A9 transport. Low-fat dairy and coffee are associated with lower serum urate in epidemiological data.

The clinical urate crystallisation threshold is 6.8 mg/dL; maintaining serum urate below 6.0 mg/dL is the standard prevention target.

Interactions

With rs6814664 (SLC2A9 intronic, 292 bp downstream): rs6814664 is the nearest characterised SLC2A9 intronic risk variant (C allele = risk) and the two SNPs share the same population frequency gradient. Individuals carrying both A at rs4519796 and C at rs6814664 carry the full SLC2A9 intronic risk haplotype in this region of the gene.

With rs3733591 (SLC2A9 Arg265His missense): rs3733591 is an independent coding variant at SLC2A9 with larger per-allele urate effect (~0.65 mg/dL). A carriers at rs4519796 who also carry C at rs3733591 face additive urate burden from both regulatory and protein-level mechanisms.

With rs2231142 (ABCG2 Q141K): ABCG2 controls intestinal urate excretion while SLC2A9 controls renal reabsorption. A-allele carriers at rs4519796 who also carry the ABCG2 Q141K T allele face elevated urate from two mechanistically independent routes, substantially compounding gout risk.

With BMI: SLC2A9 intronic variant effects on serum urate are amplified at higher BMI — a replicated interaction in two independent cohorts. AA homozygotes who are overweight or obese accumulate a greater urate load than the genotype alone predicts; weight reduction has proportionally greater benefit in this group.